The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

Mon, 11th Oct 2021 10:59

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Cadence Minerals PLC, up 42% at 24.65 pence, 12-month range 11.1p-32.49p. Receives confirmation from its secured bank creditors that they have obtained approval from their credit committees for the proposed terms of a settlement agreement, paving the way for Cadence to vest an initial 20% in the Amapa iron ore project in Brazil. A joint venture between Cadence and Indo Sino Trade Pte Ltd will own 99.9% of DEV Mineracao SA, the owner of the Amapa project. "Today's announcement is a landmark for Amapa, both in terms of certainty for DEV employees, the wider Amapa community and for Cadence shareholders," says Chair Andrew Suckling.

----------

Reneuron Group PLC, up 31% at 123.80p, 12-month 70p-153.78p. The biotechnology company reports positive data that provides "clear pre-clinical proof-of-concept" that its novel exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases. "These results are a key milestone for our exosome delivery technology, establishing clear proof of concept in vivo, which more accurately imitates conditions for the targeted delivery of key neurological therapeutics into the human brain," says Chief Executive Olav Hellebo.

----------

Feedback PLC, up 16% at 0.8432p, 12-month range 0.6p-1.57p. The medical imaging software company signs memorandum of understanding with Quest Teleradiology Solutions - a teleradiology organisation with customers across India, the UK and throughout Africa - to develop strategic opportunities for Bleepa, its clinical communications platform, in the "large and growing" Indian healthcare market, the UK and internationally.

----------

Oracle Power PLC, up 15% at 0.385p, 12-month 0.3p-0.75p. The natural resources project developer signs non-exclusive co-operation agreement with PowerChina International Group Ltd to jointly develop a green hydrogen production facility in Pakistan. It is targeting 400 megawatt capacity hydrogen plant, with planned output of around 150,000 kilograms per day.

----------

AIM - LOSERS

----------

ASOS PLC, down 11% at 2,474p, 12-month range 2,300p-5,994.95p. The online fashion retailer posts jump in annual profit, but warns on year ahead and announces departure of chief executive. Adjusted pretax profit for the 2022 financial year expected between around GBP110 million to GBP140 million. This is well below the GBP193.6 million registered for the financial year just ended. ASOS shakes up board to "underpin delivery of the next phase of its global growth strategy". CEO Nick Beighton is stepping down after 12 years with ASOS, including six as CEO, and a search is underway for his replacement.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 Sep 2018 14:44

ReNeuron pleased with progress on several therapy fronts

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its trading on Wednesday, as investors gathered for the firm's annual general meeting, announcing that following recent co-ordinating ethics committee approval, the first clinical site has now been initiated in the US Phase IIb study with its CTX cell therapy candidate for stroke disability.

Read more
12 Sep 2018 13:54

ReNeuron Expects To Enroll First Patient For Stroke Study Shortly

LONDON (Alliance News) - ReNeuron Group PLC said Wednesday it expects to enroll the first patient in its stroke disability study "shortly".The company said that the first clinical

Read more
5 Jul 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 6 July SVM UK Emerging FundFull Year Results Monday 9 July GroupHalf

Read more
19 Apr 2018 13:17

ReNeuron Wins GBP1.5 Million Grant For Stem Cell Therapy Development

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it is the "lead" industry participant in a new GBP1.5 million grant from the UK's innovation agency Innovate grant has to

Read more
3 Apr 2018 13:29

Portugal looks to renewables as March output tops mainland power demand

LISBON, April 3 (Reuters) - For the first time in at least four decades, Portugal's monthly renewable energy production in March exceeded power demand

Read more
26 Mar 2018 15:53

ReNeuron Now Expects hRPC Stem Cell Trial Data In First Half Of 2019

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it has decided to adjust the number of clinical sites for its CTX stem cell therapy candidate study, and now expects

Read more
5 Dec 2016 11:06

ReNeuron's first half revenues supported by new drug developments

(ShareCast News) - ReNeuron, an AIM-listed UK based developer of cell-based therapeutics, saw first half revenues double due to a series of successful drug trials. Revenues were £22,000 for the six months ended 30 September 2016 up from £11,000 in the first half of 2015. During the period, the grou

Read more
4 Dec 2016 14:45

Sunday share tips: ReNeuron, Clipper Logistics, RM Secured Direct Lending

(ShareCast News) - Shares of ReNeuron are for brave investors only, said the Sunday Times' Inside the City column. The stem cell pioneer is scheduled to publish the results of second-phase clinical trials of its potential stroke paralysis treatment alongside its interim results on Monday. ReNeuron's

Read more
6 Sep 2016 11:38

ReNeuron reports positive progress in clinical trials

(ShareCast News) - UK-based developer of cell-based therapeutics ReNeuron Group provided a trading update ahead of its annual general meeting on Tuesday. The AIM-traded firm reported that all patients have been treated in the PISCES II Phase II clinical trial of its CTX cell therapy candidate for pa

Read more
7 Jul 2016 09:37

ReNeuron Annual Loss Widens As Product Trials Ramp Up

Read more
4 Jul 2016 15:16

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
13 Jun 2016 07:58

ReNeuron Completes Phase II Stroke Therapy Trial Patient Recruitment

Read more
9 Jun 2016 08:55

ReNeuron Selects Glioblastoma Multiforme As First Clinical Target

Read more
8 Jun 2016 08:36

ReNeuron Progressing Blindness Candidate Through Phase I/II Trial

Read more
15 Mar 2016 09:52

ReNeuron Says First Patient Treated For Retinitis Pigmentosa

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.